Auspex Pharmaceuticals Raises $35M

La Jolla-based Auspex Pharmaceuticals, a biopharmaceuticals firm aiming at treating hyperkinetic movement disorders, announced this morning that it has raised $35M in two separate financings. According to the company, it raised $20M in a Series E equity financing, and also raised $15M in a four year, venture loan. The equity funding was led by Deerfield Management Company, along with its existing investors, which include Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, BioMed Ventures and Costa Verde Capital. The venture loan came from Oxford Finance. Auspex is developing treatments for Huntington's disease, Tourette syndrome, and Tardive Dyskinesia. The firm's lead program is a treatment for Huntington's disease, and is in Phase 3 clinical development. More information »